Beta1-adrenoceptor antagonist, metoprolol attenuates cardiac myocyte Ca2+ handling dysfunction in rats with pulmonary artery hypertension

Right heart failure is the major cause of death in Pulmonary Artery Hypertension (PAH) patients but is not a current, specific therapeutic target. Pre-clinical studies have shown that adrenoceptor blockade can improve cardiac function but the mechanisms of action within right ventricular (RV) myocyt...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of molecular and cellular cardiology 2018-07, Vol.120, p.74-83
Hauptverfasser: Fowler, Ewan D., Drinkhill, Mark J., Norman, Ruth, Pervolaraki, Eleftheria, Stones, Rachel, Steer, Emma, Benoist, David, Steele, Derek S., Calaghan, Sarah C., White, Ed
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 83
container_issue
container_start_page 74
container_title Journal of molecular and cellular cardiology
container_volume 120
creator Fowler, Ewan D.
Drinkhill, Mark J.
Norman, Ruth
Pervolaraki, Eleftheria
Stones, Rachel
Steer, Emma
Benoist, David
Steele, Derek S.
Calaghan, Sarah C.
White, Ed
description Right heart failure is the major cause of death in Pulmonary Artery Hypertension (PAH) patients but is not a current, specific therapeutic target. Pre-clinical studies have shown that adrenoceptor blockade can improve cardiac function but the mechanisms of action within right ventricular (RV) myocytes are unknown. We tested whether the β1–adrenoceptor blocker metoprolol could improve RV myocyte function in an animal model of PAH, by attenuating adverse excitation-contraction coupling remodeling. PAH with RV failure was induced in rats by monocrotaline injection. When PAH was established, animals were given 10 mg/kg/day metoprolol (MCT + BB) or vehicle (MCT). The median time to the onset of heart failure signs was delayed from 23 days (MCT), to 31 days (MCT + BB). At 23 ± 1 days post-injection, MCT + BB showed improved in vivo cardiac function, measured by echocardiography. RV hypertrophy was reduced despite persistent elevated afterload. RV myocyte contractility during field stimulation was improved at higher pacing frequencies in MCT + BB. Preserved t-tubule structure, more uniform evoked Ca2+ release, increased SERCA2a expression and faster ventricular repolarization (measured in vivo by telemetry) may account for the improved contractile function. Sarcoplasmic reticulum Ca2+ overload was prevented in MCT + BB myocytes resulting in fewer spontaneous Ca2+ waves, with a lower pro-arrhythmic potential. Our novel finding of attenuation of defects in excitation contraction coupling by β1–adrenoceptor blockade with delays in the onset of HF, identifies the RV as a promising therapeutic target in PAH. Moreover, our data suggest existing therapies for left ventricular failure may also be beneficial in PAH induced RV failure. •β1–adrenoceptor blocker metoprolol delayed the onset of right heart failure in PAH rats.•Metoprolol attenuated repolarisation remodelling, measured in vivo by telemetry.•Metoprolol attenuated t-tubule remodeling in single right ventricular myocytes.•Metoprolol attenuating adverse Ca2+ handling remodeling in right ventricular myocytes.•β–adrenoceptor blockade may be a useful additional treatment for PAH.
doi_str_mv 10.1016/j.yjmcc.2018.05.015
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6013283</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0022282818301767</els_id><sourcerecordid>2046606263</sourcerecordid><originalsourceid>FETCH-LOGICAL-c366t-d81b2ddcae5fa6c1e4b6da78a9a66d6e08082e3e07322a9eca68f118fea615403</originalsourceid><addsrcrecordid>eNp9kcGO1DAMhisEYoeFJ-CSIxK0OGmbSQ8gwYgFpJW4wDnyJO5MRm1SknRRH4G3psOsVuLCyZb8_78tf0XxkkPFgcu3p2o5jcZUAriqoK2At4-KDYeuLVWrmsfFBkCIUiihropnKZ0AoGvq-mlxJToFWxDNpvj9kTLyEm0kHwxNOUSGPuMheJfyGzZSDlMMQxgY5kx-xkyJGYzWoWHjEsySie1QvGZH9HZw_sDskvrZm-yCZ86ziDmxXy4f2TQPY_AYF4Yx01qOy0Rr59MqfV486XFI9OK-Xhc_bj59330pb799_rr7cFuaWspcWsX3wlqD1PYoDadmLy1uFXYopZUECpSgmmBbC4EdGZSq51z1hJK3DdTXxftL7jTvR7KGfI446Cm6cb1MB3T634l3R30Id1oCr4Wq14BX9wEx_JwpZT26ZGgY0FOYkxbQSAlSyLO0vkhNDClF6h_WcNBniPqk_0LUZ4gaWr1CXF3vLi5a33DnKOpkHHlD1kUyWdvg_uv_A7U9qrE</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2046606263</pqid></control><display><type>article</type><title>Beta1-adrenoceptor antagonist, metoprolol attenuates cardiac myocyte Ca2+ handling dysfunction in rats with pulmonary artery hypertension</title><source>ScienceDirect Journals (5 years ago - present)</source><creator>Fowler, Ewan D. ; Drinkhill, Mark J. ; Norman, Ruth ; Pervolaraki, Eleftheria ; Stones, Rachel ; Steer, Emma ; Benoist, David ; Steele, Derek S. ; Calaghan, Sarah C. ; White, Ed</creator><creatorcontrib>Fowler, Ewan D. ; Drinkhill, Mark J. ; Norman, Ruth ; Pervolaraki, Eleftheria ; Stones, Rachel ; Steer, Emma ; Benoist, David ; Steele, Derek S. ; Calaghan, Sarah C. ; White, Ed</creatorcontrib><description>Right heart failure is the major cause of death in Pulmonary Artery Hypertension (PAH) patients but is not a current, specific therapeutic target. Pre-clinical studies have shown that adrenoceptor blockade can improve cardiac function but the mechanisms of action within right ventricular (RV) myocytes are unknown. We tested whether the β1–adrenoceptor blocker metoprolol could improve RV myocyte function in an animal model of PAH, by attenuating adverse excitation-contraction coupling remodeling. PAH with RV failure was induced in rats by monocrotaline injection. When PAH was established, animals were given 10 mg/kg/day metoprolol (MCT + BB) or vehicle (MCT). The median time to the onset of heart failure signs was delayed from 23 days (MCT), to 31 days (MCT + BB). At 23 ± 1 days post-injection, MCT + BB showed improved in vivo cardiac function, measured by echocardiography. RV hypertrophy was reduced despite persistent elevated afterload. RV myocyte contractility during field stimulation was improved at higher pacing frequencies in MCT + BB. Preserved t-tubule structure, more uniform evoked Ca2+ release, increased SERCA2a expression and faster ventricular repolarization (measured in vivo by telemetry) may account for the improved contractile function. Sarcoplasmic reticulum Ca2+ overload was prevented in MCT + BB myocytes resulting in fewer spontaneous Ca2+ waves, with a lower pro-arrhythmic potential. Our novel finding of attenuation of defects in excitation contraction coupling by β1–adrenoceptor blockade with delays in the onset of HF, identifies the RV as a promising therapeutic target in PAH. Moreover, our data suggest existing therapies for left ventricular failure may also be beneficial in PAH induced RV failure. •β1–adrenoceptor blocker metoprolol delayed the onset of right heart failure in PAH rats.•Metoprolol attenuated repolarisation remodelling, measured in vivo by telemetry.•Metoprolol attenuated t-tubule remodeling in single right ventricular myocytes.•Metoprolol attenuating adverse Ca2+ handling remodeling in right ventricular myocytes.•β–adrenoceptor blockade may be a useful additional treatment for PAH.</description><identifier>ISSN: 0022-2828</identifier><identifier>ISSN: 1095-8584</identifier><identifier>EISSN: 1095-8584</identifier><identifier>DOI: 10.1016/j.yjmcc.2018.05.015</identifier><identifier>PMID: 29807024</identifier><language>eng</language><publisher>Elsevier Ltd</publisher><subject>Beta-blocker ; Ca2+ handling ; Cardiac myocyte ; Monocrotaline ; Pulmonary artery hypertension ; Right heart failure</subject><ispartof>Journal of molecular and cellular cardiology, 2018-07, Vol.120, p.74-83</ispartof><rights>2018 The Authors</rights><rights>Copyright © 2018 The Authors. Published by Elsevier Ltd.. All rights reserved.</rights><rights>2018 The Authors 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c366t-d81b2ddcae5fa6c1e4b6da78a9a66d6e08082e3e07322a9eca68f118fea615403</citedby><cites>FETCH-LOGICAL-c366t-d81b2ddcae5fa6c1e4b6da78a9a66d6e08082e3e07322a9eca68f118fea615403</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.yjmcc.2018.05.015$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>230,314,780,784,885,3550,27924,27925,45995</link.rule.ids></links><search><creatorcontrib>Fowler, Ewan D.</creatorcontrib><creatorcontrib>Drinkhill, Mark J.</creatorcontrib><creatorcontrib>Norman, Ruth</creatorcontrib><creatorcontrib>Pervolaraki, Eleftheria</creatorcontrib><creatorcontrib>Stones, Rachel</creatorcontrib><creatorcontrib>Steer, Emma</creatorcontrib><creatorcontrib>Benoist, David</creatorcontrib><creatorcontrib>Steele, Derek S.</creatorcontrib><creatorcontrib>Calaghan, Sarah C.</creatorcontrib><creatorcontrib>White, Ed</creatorcontrib><title>Beta1-adrenoceptor antagonist, metoprolol attenuates cardiac myocyte Ca2+ handling dysfunction in rats with pulmonary artery hypertension</title><title>Journal of molecular and cellular cardiology</title><description>Right heart failure is the major cause of death in Pulmonary Artery Hypertension (PAH) patients but is not a current, specific therapeutic target. Pre-clinical studies have shown that adrenoceptor blockade can improve cardiac function but the mechanisms of action within right ventricular (RV) myocytes are unknown. We tested whether the β1–adrenoceptor blocker metoprolol could improve RV myocyte function in an animal model of PAH, by attenuating adverse excitation-contraction coupling remodeling. PAH with RV failure was induced in rats by monocrotaline injection. When PAH was established, animals were given 10 mg/kg/day metoprolol (MCT + BB) or vehicle (MCT). The median time to the onset of heart failure signs was delayed from 23 days (MCT), to 31 days (MCT + BB). At 23 ± 1 days post-injection, MCT + BB showed improved in vivo cardiac function, measured by echocardiography. RV hypertrophy was reduced despite persistent elevated afterload. RV myocyte contractility during field stimulation was improved at higher pacing frequencies in MCT + BB. Preserved t-tubule structure, more uniform evoked Ca2+ release, increased SERCA2a expression and faster ventricular repolarization (measured in vivo by telemetry) may account for the improved contractile function. Sarcoplasmic reticulum Ca2+ overload was prevented in MCT + BB myocytes resulting in fewer spontaneous Ca2+ waves, with a lower pro-arrhythmic potential. Our novel finding of attenuation of defects in excitation contraction coupling by β1–adrenoceptor blockade with delays in the onset of HF, identifies the RV as a promising therapeutic target in PAH. Moreover, our data suggest existing therapies for left ventricular failure may also be beneficial in PAH induced RV failure. •β1–adrenoceptor blocker metoprolol delayed the onset of right heart failure in PAH rats.•Metoprolol attenuated repolarisation remodelling, measured in vivo by telemetry.•Metoprolol attenuated t-tubule remodeling in single right ventricular myocytes.•Metoprolol attenuating adverse Ca2+ handling remodeling in right ventricular myocytes.•β–adrenoceptor blockade may be a useful additional treatment for PAH.</description><subject>Beta-blocker</subject><subject>Ca2+ handling</subject><subject>Cardiac myocyte</subject><subject>Monocrotaline</subject><subject>Pulmonary artery hypertension</subject><subject>Right heart failure</subject><issn>0022-2828</issn><issn>1095-8584</issn><issn>1095-8584</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp9kcGO1DAMhisEYoeFJ-CSIxK0OGmbSQ8gwYgFpJW4wDnyJO5MRm1SknRRH4G3psOsVuLCyZb8_78tf0XxkkPFgcu3p2o5jcZUAriqoK2At4-KDYeuLVWrmsfFBkCIUiihropnKZ0AoGvq-mlxJToFWxDNpvj9kTLyEm0kHwxNOUSGPuMheJfyGzZSDlMMQxgY5kx-xkyJGYzWoWHjEsySie1QvGZH9HZw_sDskvrZm-yCZ86ziDmxXy4f2TQPY_AYF4Yx01qOy0Rr59MqfV486XFI9OK-Xhc_bj59330pb799_rr7cFuaWspcWsX3wlqD1PYoDadmLy1uFXYopZUECpSgmmBbC4EdGZSq51z1hJK3DdTXxftL7jTvR7KGfI446Cm6cb1MB3T634l3R30Id1oCr4Wq14BX9wEx_JwpZT26ZGgY0FOYkxbQSAlSyLO0vkhNDClF6h_WcNBniPqk_0LUZ4gaWr1CXF3vLi5a33DnKOpkHHlD1kUyWdvg_uv_A7U9qrE</recordid><startdate>201807</startdate><enddate>201807</enddate><creator>Fowler, Ewan D.</creator><creator>Drinkhill, Mark J.</creator><creator>Norman, Ruth</creator><creator>Pervolaraki, Eleftheria</creator><creator>Stones, Rachel</creator><creator>Steer, Emma</creator><creator>Benoist, David</creator><creator>Steele, Derek S.</creator><creator>Calaghan, Sarah C.</creator><creator>White, Ed</creator><general>Elsevier Ltd</general><general>Academic Press</general><scope>6I.</scope><scope>AAFTH</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>201807</creationdate><title>Beta1-adrenoceptor antagonist, metoprolol attenuates cardiac myocyte Ca2+ handling dysfunction in rats with pulmonary artery hypertension</title><author>Fowler, Ewan D. ; Drinkhill, Mark J. ; Norman, Ruth ; Pervolaraki, Eleftheria ; Stones, Rachel ; Steer, Emma ; Benoist, David ; Steele, Derek S. ; Calaghan, Sarah C. ; White, Ed</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c366t-d81b2ddcae5fa6c1e4b6da78a9a66d6e08082e3e07322a9eca68f118fea615403</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Beta-blocker</topic><topic>Ca2+ handling</topic><topic>Cardiac myocyte</topic><topic>Monocrotaline</topic><topic>Pulmonary artery hypertension</topic><topic>Right heart failure</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fowler, Ewan D.</creatorcontrib><creatorcontrib>Drinkhill, Mark J.</creatorcontrib><creatorcontrib>Norman, Ruth</creatorcontrib><creatorcontrib>Pervolaraki, Eleftheria</creatorcontrib><creatorcontrib>Stones, Rachel</creatorcontrib><creatorcontrib>Steer, Emma</creatorcontrib><creatorcontrib>Benoist, David</creatorcontrib><creatorcontrib>Steele, Derek S.</creatorcontrib><creatorcontrib>Calaghan, Sarah C.</creatorcontrib><creatorcontrib>White, Ed</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of molecular and cellular cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fowler, Ewan D.</au><au>Drinkhill, Mark J.</au><au>Norman, Ruth</au><au>Pervolaraki, Eleftheria</au><au>Stones, Rachel</au><au>Steer, Emma</au><au>Benoist, David</au><au>Steele, Derek S.</au><au>Calaghan, Sarah C.</au><au>White, Ed</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Beta1-adrenoceptor antagonist, metoprolol attenuates cardiac myocyte Ca2+ handling dysfunction in rats with pulmonary artery hypertension</atitle><jtitle>Journal of molecular and cellular cardiology</jtitle><date>2018-07</date><risdate>2018</risdate><volume>120</volume><spage>74</spage><epage>83</epage><pages>74-83</pages><issn>0022-2828</issn><issn>1095-8584</issn><eissn>1095-8584</eissn><abstract>Right heart failure is the major cause of death in Pulmonary Artery Hypertension (PAH) patients but is not a current, specific therapeutic target. Pre-clinical studies have shown that adrenoceptor blockade can improve cardiac function but the mechanisms of action within right ventricular (RV) myocytes are unknown. We tested whether the β1–adrenoceptor blocker metoprolol could improve RV myocyte function in an animal model of PAH, by attenuating adverse excitation-contraction coupling remodeling. PAH with RV failure was induced in rats by monocrotaline injection. When PAH was established, animals were given 10 mg/kg/day metoprolol (MCT + BB) or vehicle (MCT). The median time to the onset of heart failure signs was delayed from 23 days (MCT), to 31 days (MCT + BB). At 23 ± 1 days post-injection, MCT + BB showed improved in vivo cardiac function, measured by echocardiography. RV hypertrophy was reduced despite persistent elevated afterload. RV myocyte contractility during field stimulation was improved at higher pacing frequencies in MCT + BB. Preserved t-tubule structure, more uniform evoked Ca2+ release, increased SERCA2a expression and faster ventricular repolarization (measured in vivo by telemetry) may account for the improved contractile function. Sarcoplasmic reticulum Ca2+ overload was prevented in MCT + BB myocytes resulting in fewer spontaneous Ca2+ waves, with a lower pro-arrhythmic potential. Our novel finding of attenuation of defects in excitation contraction coupling by β1–adrenoceptor blockade with delays in the onset of HF, identifies the RV as a promising therapeutic target in PAH. Moreover, our data suggest existing therapies for left ventricular failure may also be beneficial in PAH induced RV failure. •β1–adrenoceptor blocker metoprolol delayed the onset of right heart failure in PAH rats.•Metoprolol attenuated repolarisation remodelling, measured in vivo by telemetry.•Metoprolol attenuated t-tubule remodeling in single right ventricular myocytes.•Metoprolol attenuating adverse Ca2+ handling remodeling in right ventricular myocytes.•β–adrenoceptor blockade may be a useful additional treatment for PAH.</abstract><pub>Elsevier Ltd</pub><pmid>29807024</pmid><doi>10.1016/j.yjmcc.2018.05.015</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0022-2828
ispartof Journal of molecular and cellular cardiology, 2018-07, Vol.120, p.74-83
issn 0022-2828
1095-8584
1095-8584
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6013283
source ScienceDirect Journals (5 years ago - present)
subjects Beta-blocker
Ca2+ handling
Cardiac myocyte
Monocrotaline
Pulmonary artery hypertension
Right heart failure
title Beta1-adrenoceptor antagonist, metoprolol attenuates cardiac myocyte Ca2+ handling dysfunction in rats with pulmonary artery hypertension
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T05%3A14%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Beta1-adrenoceptor%20antagonist,%20metoprolol%20attenuates%20cardiac%20myocyte%20Ca2+%20handling%20dysfunction%20in%20rats%20with%20pulmonary%20artery%20hypertension&rft.jtitle=Journal%20of%20molecular%20and%20cellular%20cardiology&rft.au=Fowler,%20Ewan%20D.&rft.date=2018-07&rft.volume=120&rft.spage=74&rft.epage=83&rft.pages=74-83&rft.issn=0022-2828&rft.eissn=1095-8584&rft_id=info:doi/10.1016/j.yjmcc.2018.05.015&rft_dat=%3Cproquest_pubme%3E2046606263%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2046606263&rft_id=info:pmid/29807024&rft_els_id=S0022282818301767&rfr_iscdi=true